Drug manufacturers and partners look toward advancements in post-COVID world
FiercePharma, Willis Chandler and Jan Burkett
With a global pandemic barely in the rearview mirror, the gaze of the pharmaceutical industry is clearly focused on what lies ahead.
The tough lessons taught by COVID-19 have reshaped the global pharmaceutical supply chain and how manufacturers approach bringing new treatments to market. Pharma has also placed emphasis on coordination and communication with downstream stakeholders like distributors, payors, physicians, pharmacies and the ultimate end user—the patient.
For the full article, please visit FiercePharma.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.